Injection of botulinum toxin type A into the external urethral sphincter for male patients suffering from chronic prostatitis/chronic pelvic pain syndrome (NIH [National Institute of Health category III]): a prospective, double-blind and placebo-controlled clinical trial

Trial Profile

Injection of botulinum toxin type A into the external urethral sphincter for male patients suffering from chronic prostatitis/chronic pelvic pain syndrome (NIH [National Institute of Health category III]): a prospective, double-blind and placebo-controlled clinical trial

Discontinued
Phase of Trial: Phase III

Latest Information Update: 31 Jan 2014

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Prostatitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Jan 2014 According to ClinicalTrials.gov record trial status changed to discontinued.
    • 20 Aug 2010 Planned end date changed from 1 Apr 2010 to 1 Apr 2013 as reported by ClinicalTrials.gov.
    • 20 Aug 2010 Additional lead trial investigator (Patrick Markart) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top